Navigation Links
MAP Pharmaceuticals to Present at Upcoming Investor Conferences
Date:5/1/2012

MOUNTAIN VIEW, Calif., May 1, 2012 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will participate in the following investor conferences in May 2012:

Deutsche Bank 37th Annual Healthcare Conference
Tuesday, May 8, at 8:40 a.m. ET in Boston

Bank of America Merrill Lynch 2012 Healthcare Conference
Tuesday, May 15, at 3:40 p.m. PT in Las Vegas

A live webcast of each event will be available on the Investor Relations section of MAP Pharmaceuticals' website at http://www.mappharma.com. A replay also will be available within 24 hours for seven days following each presentation.

About MAP Pharmaceuticals

MAP Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing new therapies to address undermet patient needs in neurology. The Company is developing LEVADEX®, an orally inhaled investigational drug for the potential acute treatment of migraine. The U.S. Food and Drug Administration reviewed the New Drug Application for LEVADEX and on March 26, 2012, the Company received a Complete Response letter. MAP Pharmaceuticals has entered into a collaboration agreement with Allergan, Inc. to co-promote LEVADEX to neurologists and pain specialists in the U.S. and Canada. The Company also applies its proprietary drug particle and inhalation technologies to generate new pipeline opportunities by enhancing the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.

CONTACT:
Lisa Borland
MAP Pharmaceuticals, Inc.
650-386-3122
lborland@mappharma.com


'/>"/>
SOURCE MAP Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... , Aug. 31, 2015  Asterias Biotherapeutics, ... on the emerging field of regenerative medicine, today ... at Chicago -based Rush University ... evaluating activity of escalating doses of AST-OPC1 (oligodendrocyte ... and motor complete cervical spinal cord injury (SCI). ...
(Date:8/31/2015)... Bionomics Limited (ASX:BNO, ADR:BMICY), a biopharmaceutical company ... for the treatment of diseases of the central nervous ... IND submission has passed review by the US Food ... Phase 1 clinical trial in patients with metastatic colon ... to 31 December 2015. Bionomics, CEO & ...
(Date:8/30/2015)... LONDRES, August 30, 2015 ... de l cuidado al paciente ... trayecto   Royal Philips  (NYSE: ... de IntelliSpace Cardiovascular , un sistema web de ... para acceder, analizar y compartir imágenes cardiovasculares e información ...
Breaking Medicine Technology:Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 2Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 3Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 4Philips presenta IntelliSpace Cardiovascular en el Congreso ESC 2015 2Philips presenta IntelliSpace Cardiovascular en el Congreso ESC 2015 3
(Date:8/31/2015)... ... 31, 2015 , ... Finnleo , a leader in the sauna industry, ... 3rd quarter, the newly re-styled and re-designed “Hallmark Series” updates the Passport series with ... models include more glass and a more upscale feel than the current Passport a ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... ... provider of the CME-certified annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for ... be held Nov. 4 – 6 in New York City. The annual legacy ...
(Date:8/31/2015)... ... August 31, 2015 , ... Wyoming Medical ... (CAC) software for its Clinical Documentation Improvement (CDI) and medical coding needs. Based ... ICD-10 solution - ezCAC is an enterprise-level coding solution that combines CDI, Coding, ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... be at a greater risk for injury, potentially because they are more susceptible ... Pittsburgh Graduate School of Public Health analysis discovered. , The research, published ...
(Date:8/31/2015)... NY (PRWEB) , ... August 31, 2015 , ... ... that enable users to develop skills and assess their competencies in managing challenging ... research, will present at the Defense Centers of Excellence for Psychological Health ...
Breaking Medicine News(10 mins):Health News:Finnleo Introduces Hallmark Series Saunas 2Health News:Physicians’ Education Resource® Seeks Abstracts for the Upcoming Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® 2Health News:Physicians’ Education Resource® Seeks Abstracts for the Upcoming Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® 3Health News:Physicians’ Education Resource® Seeks Abstracts for the Upcoming Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® 4Health News:Wyoming Medical Center Selects ezDI’s CAC/CDI Solution Based on Integrated Healthcare Data Management, Workflow Design and ROI 2Health News:Wyoming Medical Center Selects ezDI’s CAC/CDI Solution Based on Integrated Healthcare Data Management, Workflow Design and ROI 3Health News:Wyoming Medical Center Selects ezDI’s CAC/CDI Solution Based on Integrated Healthcare Data Management, Workflow Design and ROI 4Health News:Television Viewing Linked to Higher Injury Risk in Hostile People 2Health News:Television Viewing Linked to Higher Injury Risk in Hostile People 3Health News:Kognito’s Glenn Albright to Present at DCoE Summit 2
... Trust Presents Case Study for Patient Tracking System at London Conference ... ... Lombardi, a leader in http://www.lombardi.com/ [business process management (BPM) __title__ business ... been selected to present at the IRM UK,s upcoming BPM Europe ...
... 24 Andrew Engel,M.D., Roland Moskowitz, M.D., Peter ... Mayo Clinic Distinguished Alumni Award. The awards,were presented ... Alumni Association on,Sept. 11, 2008, at the Foundation ... alumni to the field of medicine,including medical practice, ...
... officials are urging more Americans than ever before to ... (HealthDay News) -- With flu season fast approaching, U.S. ... be a better match for the circulating influenza strains ... only do officials believe this year,s vaccine will be ...
... BodyTech.com hold contest for one guy and one gal to,be ... NORTH BERGEN, N.J., Sept. 24 If you,ve ever ... very, very hot in Vegas. With,the help of The Vitamin ... is offering an opportunity for two participants to,realize their dream ...
... DALLAS, Sept. 24 As the presidential political ... prevention heats up, one leading,prevention authority thinks some ... president of U.S. Preventive Medicine(R), the,leader in disease ... for itself., (Logo: http://www.newscom.com/cgi-bin/prnh/20080506/NETU129LOGO ), ...
... behavior in inquiries about patient mood symptoms and the ... University of Rochester Medical Center researchers. , "Some doctors, ... loathe to broach sensitive topics such as depression or ... at the Medical Center and lead author of an ...
Cached Medicine News:Health News:UCLH to Discuss Using Business Process Management to Meet Government Referral-To-Treatment Mandate at IRM BPM Europe 2008 2Health News:Mayo Clinic Announces 2008 Distinguished Alumni Awardees 2Health News:Flu Vaccine Should Be More Effective: CDC 2Health News:Flu Vaccine Should Be More Effective: CDC 3Health News:Who Will Be The 'Hot Bod' at the Olympia? 2Health News:Presidential Debate Over Health Care Costs Highlights Need for Preventive Health Care 2Health News:Presidential Debate Over Health Care Costs Highlights Need for Preventive Health Care 3Health News:Personality can hamper a physician's assessment of depression 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: